Cardlytics (CDLX) Tops Q3 EPS by 18c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
Cardlytics (NASDAQ: CDLX) reported Q3 EPS of $0.03, $0.18 better than the analyst estimate of ($0.15). Revenue for the quarter ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)